Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CHRS Stock Forecast 2026-2027
$1.60
Current Price
$205.48M
Market Cap
Buy 4
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CHRS Price Targets
+337.5%
To High Target of $7.00
+275.0%
To Median Target of $6.00
+150.0%
To Low Target of $4.00
CHRS Price Momentum
+4.6%
1 Week Change
+15.1%
1 Month Change
+9.6%
1 Year Change
+12.7%
Year-to-Date Change
-15.3%
From 52W High of $1.89
+125.4%
From 52W Low of $0.71
📊 TOP ANALYST CALLS
Did CHRS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Coherus is one of their latest high-conviction picks.
Latest CHRS Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, CHRS has a bullish consensus with a median price target of $6.00 (ranging from $4.00 to $7.00). The overall analyst rating is N/A (N/A/10). Currently trading at $1.60, the median forecast implies a 275.0% upside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Douglas Tsao at HC Wainwright & Co., projecting a 337.5% upside. Conversely, the most conservative target is provided by Jason McCarthy at Maxim Group, suggesting a 150.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CHRS Analyst Ratings
4
Buy
1
Hold
0
Sell
CHRS Price Target Range
Low
$4.00
Average
$6.00
High
$7.00
Current: $1.60
Latest CHRS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CHRS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 4, 2025 | Maxim Group | Jason McCarthy | Buy | Upgrade | $4.00 |
| Apr 29, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $7.00 |
| Apr 24, 2025 | UBS | Ashwani Verma | Neutral | Maintains | $1.05 |
| Mar 11, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $7.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $7.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 5, 2024 | Baird | Colleen Kusy | Outperform | Maintains | $6.00 |
| Dec 4, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $7.00 |
| Nov 8, 2024 | Baird | Colleen Kusy | Outperform | Maintains | $4.00 |
| Nov 7, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $12.00 |
| Sep 16, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $12.00 |
| Aug 16, 2024 | UBS | Ashwani Verma | Neutral | Downgrade | $1.50 |
| Aug 5, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $12.00 |
| Jul 1, 2024 | Baird | Colleen Kusy | Outperform | Maintains | $8.00 |
| May 24, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $12.00 |
| May 13, 2024 | Truist Securities | Robyn Karnauskas | Buy | Maintains | $7.00 |
| May 10, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $12.00 |
| Mar 20, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $11.00 |
| Mar 14, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $13.00 |
| Jan 23, 2024 | Truist Securities | Robyn Karnauskas | Buy | Maintains | $8.00 |
Coherus Biosciences Inc. (CHRS) Competitors
The following stocks are similar to Coherus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Coherus Biosciences Inc. (CHRS) Financial Data
Coherus Biosciences Inc. has a market capitalization of $205.48M with a P/E ratio of 3.0x. The company generates $277.73M in trailing twelve-month revenue with a 55.8% profit margin.
Revenue growth is +91.2% quarter-over-quarter, while maintaining an operating margin of -365.0% and return on equity of -21.6%.
Valuation Metrics
Market Cap
$205.48M
Enterprise Value
$62.09M
P/E Ratio
3.0x
PEG Ratio
0.0x
Price/Sales
0.7x
Growth & Margins
Revenue Growth (YoY)
+91.2%
Gross Margin
+67.8%
Operating Margin
-365.0%
Net Margin
+55.8%
EPS Growth
-83.7%
Financial Health
Cash/Price Ratio
+99.1%
Current Ratio
1.2x
Debt/Equity
61.9x
ROE
-21.6%
ROA
-10.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Coherus Biosciences Inc. (CHRS) Business Model
About Coherus Biosciences Inc.
What They Do
Develops and commercializes biosimilar products.
Business Model
Coherus Biosciences generates revenue by developing, manufacturing, and selling biosimilar therapies that are highly similar to existing biological medicines. By offering these cost-effective alternatives, the company aims to improve access to essential treatments in oncology, ophthalmology, and immunology, thus addressing the growing demand for affordable healthcare solutions.
Additional Information
Founded in 2010 and based in Redwood City, California, Coherus operates in a highly regulated market. The company collaborates with healthcare providers, payers, and patients to enhance the availability of its products, and it focuses on expanding its portfolio through specialized research and development. This commitment positions Coherus as a significant player in the biotechnology sector, contributing to healthcare sustainability.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
158
CEO
Mr. Dennis M. Lanfear
Country
United States
IPO Year
2014
Website
www.coherus.comCoherus Biosciences Inc. (CHRS) Latest News & Analysis
Latest News
Quick Summary
Coherus Oncology announced its investigational anti-CCR8 monoclonal antibody, tagmokitug, demonstrating high selectivity and efficacy in targeting CCR8+ cells in tumors, as detailed in a recent publication.
Why It Matters
The announcement highlights Coherus Oncology's promising new therapy targeting CCR8, indicating potential efficacy in solid tumors, which could enhance its market position and attract investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Coherus Oncology (NASDAQ: CHRS) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 10:30 a.m. PT. The event will be accessible via webcast.
Why It Matters
Coherus Oncology's presentation at a major healthcare conference could signal strategic developments, impacting investor sentiment and stock performance in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Coherus Oncology holds a 'Buy' rating due to a strong clinical pipeline and undervalued assets. Key catalysts include mid-2026 data for casdozokitug and CHS-114, with no major milestones expected in Q1 2026.
Why It Matters
Coherus Oncology's strong 'Buy' rating, driven by its clinical pipeline and cash position, suggests potential growth. Pipeline success is crucial for profitability, impacting future stock performance.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Long-term data shows potential survival benefits for patients with recurrent or metastatic nasopharyngeal carcinoma using LOQTORZI combined with chemotherapy.
Why It Matters
Positive long-term survival data for LOQTORZI in treating nasopharyngeal carcinoma may boost investor confidence, indicating strong product efficacy and potential revenue growth for the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Coherus Oncology, Inc. (CHRS) Presents at UBS Global Healthcare Conference 2025 Transcript
2 months ago
Quick Summary
Coherus Oncology, Inc. (CHRS) will present at the UBS Global Healthcare Conference on November 10, 2025, featuring CEO Dennis Lanfear and CDO Theresa Lavallee.
Why It Matters
Coherus Oncology's participation in the UBS Global Healthcare Conference highlights its visibility in the healthcare sector and potential investor interest, impacting stock performance and market perception.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Coherus Oncology, Inc. (CHRS) will hold its Q3 2025 earnings call on November 6, 2025, at 5:00 PM EST, featuring key executives and analysts from various firms.
Why It Matters
The earnings call for Coherus Oncology will provide insights into financial performance and strategic direction, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About CHRS Stock
What is Coherus Biosciences Inc.'s (CHRS) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Coherus Biosciences Inc. (CHRS) has a median price target of $6.00. The highest price target is $7.00 and the lowest is $4.00.
Is CHRS stock a good investment in 2026?
According to current analyst ratings, CHRS has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CHRS stock?
Wall Street analysts predict CHRS stock could reach $6.00 in the next 12 months. This represents a 275.0% increase from the current price of $1.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Coherus Biosciences Inc.'s business model?
Coherus Biosciences generates revenue by developing, manufacturing, and selling biosimilar therapies that are highly similar to existing biological medicines. By offering these cost-effective alternatives, the company aims to improve access to essential treatments in oncology, ophthalmology, and immunology, thus addressing the growing demand for affordable healthcare solutions.
What is the highest forecasted price for CHRS Coherus Biosciences Inc.?
The highest price target for CHRS is $7.00 from Douglas Tsao at HC Wainwright & Co., which represents a 337.5% increase from the current price of $1.60.
What is the lowest forecasted price for CHRS Coherus Biosciences Inc.?
The lowest price target for CHRS is $4.00 from Jason McCarthy at Maxim Group, which represents a 150.0% increase from the current price of $1.60.
What is the overall CHRS consensus from analysts for Coherus Biosciences Inc.?
The overall analyst consensus for CHRS is bullish. Out of 10 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are CHRS stock price projections?
Stock price projections, including those for Coherus Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 2:32 AM UTC